Is macitentan included in the medical insurance list?

Macitentan (Macitentan) is an oral endothelin receptor antagonist, mainly used to treat patients with pulmonary arterial hypertension (PAH) to reduce vasoconstriction, improve cardiac function and delay disease progression. The drug has been officially launched in China and has been included in the national medical insurance directory, providing patients with a more accessible treatment option. Being included in medical insurance means that eligible patients can enjoy a certain proportion of reimbursement, thereby reducing the financial burden and improving drug accessibility.

In terms of price, the specifications of macitentan’s original drug are10mg*30 tablets, and each box is sold in China for about 4,000 yuan. Since it has been included in medical insurance, patients can enjoy partial cost reduction according to the reimbursement policy when purchasing it in the hospital, which is of great economic significance to patients with pulmonary arterial hypertension who take medicine for a long time. In comparison, the price of generic drugs in overseas markets is even lower. For example, a box of the same specifications produced by a Lao pharmaceutical factory costs about more than 300 yuan per box, but the price will be affected by exchange rates and market fluctuations.

Inclusion in medical insurance not only reduces patients' financial pressure, but also promotes rational clinical use of drugs to a certain extent. When doctors prescribe macitentan, they will develop an individualized medication plan based on the patient's condition, cardiac function classification, and complications. During use, patients should take the medicine as directed by the doctor, and regularly review liver function, blood pressure and blood routine indicators to ensure efficacy and safety.

Overall, macitentan has been launched in China and is included in medical insurance, providing a more convenient treatment approach for patients with pulmonary hypertension. When choosing a drug purchasing channel, patients should give priority to obtaining it through regular hospitals and pharmacies to ensure drug quality and efficacy, while enjoying the financial support brought by the medical insurance reimbursement policy. With the promotion of medical insurance coverage and clinical application, more patients will be able to benefit from this targeted therapy.

Reference materials:https://www.drugs.com/